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Atherosclerotic vascular disease manifests as
a progressive narrowing of the vessel wall, and
underlies coronary artery disease (CAD) and
cerebrovascular disease. With consequences such as
myocardial infarction and stroke, atherosclerosis
remains the most frequent cause of death in the
western world. While a strong heritable component
is undisputed, the molecular inflammatory and
immune mechanisms in the evolution of the
disease are still not fully understood. By using both
animal models of disease (foremost genetically
manipulated mice) as well as human tissue, and
more recently by employing unbiased approaches
to discover genetic loci predisposing to disease
development, investigators have revealed a complex
picture of multilayered cellular processes and
molecular mechanisms. Here we highlight the
current view on atherosclerosis and provide an
updated account of the critical factors involved in
disease development, as illustrated by various
prototypic examples.
In brief, the response-to-injury hypothesis of
Russell Ross introduced the notion that monocyte―
endothelial interactions give rise to foam cells and
growth factor induced smooth muscle cell (SMC)
proliferation, triggering lesion formation.1 Our
understanding of the atherogenic process has been
considerably refined by the appreciation of sub-
endothelial ApoB lipoprotein retention containing
low density lipoprotein (LDL) in the vessel wall
under conditions of elevated concentrations of
circulating cholesterol. This may predominantly
occur at predilection sites with disturbed flow, for
example, at branch points of vessels, where
increased endothelial turnover and structural
changes in elastins and proteoglycans occur, which
permit subendothelial accumulation of LDL. In the
intima, LDL particles are prone to modifications by
reactive oxygen species or enzymes such as
myeloperoxidase or lipoxygenases released from
inflammatory cells. These oxidised lipids (oxLDL)
further trigger the expression of adhesion molecules
which contribute to intimal leucocyte recruitment.
While early ‘fatty streak’ lesions mostly comprise
lipid laden, monocyte derived, macrophage-like
foam cells, the continued accumulation of different
leucocyte subsets, their apoptotic cell death,
together with the collection of debris and choles-
terol crystals in the vessel wall, leads to the
formation of a necrotic core. Collagen and SMCs
can form a fibrous cap covering the lesion.
Classical risk factors for atherosclerosis include
hypertension (which can increase arterial wall
tension and lead to disturbed repair processes), the
pressor hormone angiotensin II system (which can
alter endothelial function, smoking, diabetes), and
cholesterol metabolism. Clinical manifestations
arise when flow limiting stenoses occur that cause
tissue ischaemia, or when thrombi form that either
result in emboli or lead to the occlusion of the
vessel. One of the conundrums that remains to be
elucidated is the fact that thrombotic events
frequently are not observed at the sites of the most
severe arterial narrowing, but occur as a conse-
quence of a thinning of the fibrous cap, for
example, by inflammatory proteases or when
being replaced with infiltrating inflammatory cells.
The identification and diagnosis of such processes
will therefore be a major objective in future
research.2 3
LIPID TRIGGERED INFLAMMATION IN
ATHEROGENESIS
An intriguing recent finding is the presence of small
cholesterol crystals in human and mouse athero-
sclerotic lesions. These crystals appear to be asso-
ciated with lesional macrophages, accumulate in
subendothelial and necrotic areas, and promote
atherogenesis by activating the NLRP3 inflamma-
some, a pattern recognition receptor platform
mediating interleukin 1b (IL1b) secretion via
caspase-1, and neutrophil recruitment.4 Whether
these crystals precede monocyte recruitment or are
formed within macrophages, and what their func-
tional role is in atherogenesis, remain to be fully
elucidated (box 1).
The formation and accumulation of foam cells
within the vessel wall is thought to be a key event
in atherosclerosis. The uptake of cholesterol entails
an array of disadvantageous signalling pathways:
differentiating macrophages upregulate scavenger
receptors (such as SR-A/B and CD36) that mediate
the majority of modified LDL uptake. Their genetic
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lesion formation, but leads to a reduction in the
expression of inflammatory genes and macrophage
apoptosis. Interestingly, CD36 cooperates with the
toll-like receptor 4 (TLR4) and TLR6 in the
inflammatory response of macrophages to athero-
genic oxLDL. Sequestered CD36 induces an intra-
cellular CD36-TLR4-TLR6 heteromerisation, which
activates NF-kB (nuclear factor k-light-chain-
enhancer of activated B cells) and chemokine
expression, and is similarly seen in proatherogenic
TLR4 activation. The importance of TLR mediated
signalling in atherosclerosis is furthermore accen-
tuated by a reduction in atherosclerosis in mice,
with a genetic deletion of TLR2, TLR4 or the TLR
signalling adaptor MyD88.
Intracellular free cholesterol can also cause an
induction of endoplasmic reticulum (ER) stress;
this may at least be mediated by the combined
signalling of CD36 with TLR2-TLR6, and promote
oxidative burst and macrophage apoptosis. The
importance of lipotoxic ER stress in atherogensis is
further highlighted by findings showing that mice
with a somatic deficiency in the ER stress effector
CHOP display a reduction in macrophage apoptosis
and plaque necrosis. Similarly, blocking fatty acid
binding protein-4 (aP2) function reduces macro-
phage apoptosis and atherogenesis by limiting
lipotoxic ER stress and reactivation of the de novo
lipogenesis and lipid desaturation.
Cholesterol is also integrated into cellular
membrane lipid rafts. Defective cholesterol efflux
due to deficiency of the ABC transporters ABCA1
and ABCG1 can enhance cholesterol-rich raft
formation in haematopoietic stem cells, increasing
surface expression of the common IL3 and gran-
ulocyte macrophage colony stimulating factor
(GM-CSF) receptor b subunit and its downstream
signalling, resulting in an enhanced myeloprolifer-
ation. Accordingly, mice with ABCA1 and ABCG1
deficient bone marrow showed accelerated athero-
sclerosis. Myeloproliferation and atherosclerosis
could be reversed by promoting cellular cholesterol
efflux to high density lipoprotein (HDL), as in
ApoA-1-transgenic mice with increased HDL
concentrations.5
Importantly, the inverse relationship between
HDL and leucocytosis/atherogenesis confirms
human correlation studies. However, HDL not only
effects reverse cholesterol transport, and transfers
cholesterol from peripheral tissue to the liver for
excretion, it has also been shown to exert anti-
inflammatory actions. However, HDL is a hetero-
geneous particle with different contents of lipids
and proteins, and clinical assays for HDL do not
reflect this. Thus, the mere increase in HDL
concentrations may not necessarily confer clinical
benefit.3
Interestingly, a high expression of the lipoprotein
associated phospholipase A2 (Lp-PLA2), which can
be deployed in the intima bound to LDL but is also
synthesised by inflammatory cells, can be detected
in human vulnerable atherosclerotic lesions. An
increased Lp-PLA2 activity correlates with pro-
atherogenic lipids and cardiovascular risk in
humans. Lp-PLA2 primarily hydrolyses oxidised
phospholipids in LDL to generate proinflammatory
mediators such as lysophosphatidylcholine (LPC)
and oxidised non-esterified fatty acids. Selective
inhibition of Lp-PLA2 with darapladib reduces
development of complex CAD in swine, limiting
LPC content, lesions with an unstable phenotype
and inflammatory gene expression. The LPC deriv-
ative lysophosphatidic acid (LPA), which is
increased in plaques and serum in hyper-
cholesterolaemia, has similarly been implicated in
atherogenesisdfor example, by mediating the
activation of and interactions between endothelial
cells, monocytes and platelets, and promoting
macrophage accumulation and lesion progression in
atherosclerosis-prone mice.2
CYTOKINES AND CHEMOKINES IN
ATHEROSCLEROSIS
A number of pro- and anti-inflammatory cytokines
controlling leucocyte recruitment and cell functions
determine lesion growth. Among the cytokines
upregulated within atherosclerotic lesions, macro-
phage migration inhibitory factor (MIF) can be
detected in endothelial cells and macrophages in
response to oxLDL. MIF is critically involved in
a number of processes, such as endothelial cell
activation, monocyte recruitment, foam cell
formation, SMC migration and extracellular matrix
destabilisation, exerting pro-inflammatory and
proatherogenic functions. The importance of MIF
during atheroprogression was strikingly demon-
strated in studies using an MIF specific antibody
that afforded true regression of established
atherosclerotic lesions (box 2).6
As another example, type I interferons (IFNs)
have been implicated in atherogenesis. Treatment
of atherosclerosis prone mice with IFNb increases
lesion size, whereas myeloid deficiency of IFNAR1,
the receptor for type I IFNs, attenuates athero-
genesis, macrophage accumulation and necrotic
core formation. These effects are at least in part
mediated by the upregulation of CCL5 production
Box 1 Atherosclerotic vascular disease: a lipid driven, inflammatory
disease
< Macrophage scavenger receptors cooperate with toll-like receptors to
respond to lipids to drive inflammation and atherogenesis.
< Cholesterol can cause endoplasmic reticulum stress (‘lipotoxic ER stress’)
that leads to macrophage apoptosis and plaque necrosis.
< Cholesterol crystals associated with lesional macrophages accumulate in
necrotic areas and promote atherogenesis by activating the NLRP3
inflammasome and recruiting neutrophils.
< Cholesterol-rich lipid rafts in the cell membrane can enhance cytokine
receptor signalling driving myeloproliferation; cholesterol efflux from these
rafts to high density lipoprotein (HDL) protects against atherosclerosis.
< Oxidised low density lipoprotein (LDL) can be hydrolysed by lipoprotein
associated phospholipase A2 to generate proinflammatory mediators, such as
lysophosphatidylcholine (LPC) or its derivate lysophosphatidic acid (LPA) that
drive inflammatory gene expression.
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by macrophages, increasing CCR5 mediated
monocyte recruitment. This may also reflect the
correlation between upregulated type I IFN signal-
ling and CCL5 expression in advanced human
lesions.
Atherogenic recruitment of leucocytes involves
sequential rolling, firm adhesion, lateral migration
and transendothelial diapedesis and is controlled by
chemokines (chemotactic cytokines), classified
according to their conserved cysteine residues, and
their corresponding G protein coupled receptors.7 In
recent years a number of leucocytes were identified
as being recruited to the vessel wall during
atherosclerosis, including neutrophils, monocytes
and T cells, as well as B cells, dendritic cells (DCs)
and mast cells.8 Given the diversity of these cell
subsets, signature combinations of chemokines
have been perceived to confer robustness and
specificity. The combined action of chemokines in
leucocyte recruitment is illustrated by the chemo-
kines CCL5 and CXCL4, which are deposited by
platelets or platelet derived microparticles during
their transient P-selectin mediated interactions on
inflamed endothelium, where they promote
atherogenic monocyte arrest. CXCL4 amplifies
CCL5 triggered monocyte arrest, and inhibition
of this synergism by blocking CCL5-CXCL4
heteromerisation reduces atherogenesis in
hyperlipidaemic mice.9
In mice, monocytes can be subdivided into at
least two different subsets. Classical Ly6Chigh cells
dominate hyperlipidaemia induced monocytosis
and invade plaques by employing the chemokine
receptors CCR2, CCR5 and CX3CR1, whereas
entry of patrolling Ly6Clow monocytes occurs less
frequently and seems to rely on CCR5. Genetic
deletion of CCL2 and CX3CR1 or CCR2 and
CX3CL1 decreases atherosclerosis compared with
single deficiencies in these proteins, which is
attributable to both attenuated hyperlipidaemia
associated blood monocytosis and reduced macro-
phage accumulation, further highlighting the
combined action of chemokines in cell recruitment.
In addition, temporal patterns of chemokine
expression during distinct phases control the
process of atherogenesis. For example, the genetic
deletion of CCR2 in mice did not prevent early
lesion formation in the abdominal aorta but rather
limited late stage plaque formation and monocyte
infiltration in the aortic root. In contrast, mouse
CXCR3 deficiency primarily delayed early athero-
sclerosis by attenuating recruitment of T helper 1
(TH1) Tcells. The lack of the CCL5 receptor CCR5
in somatic or blood cells reduced plaque formation
in mice at later stages, upregulated systemic IL10
and downregulated interferon g (IFNg), reflecting
an attenuated TH1-type response.7
Aside from the functions of chemokines in
recruitment, the absence of CX3CR1 or CX3CL1
has been shown to reduce Ly6Clow blood monocyte
concentrations under steady state and inflamma-
tory conditions, which could be rescued by
expression of anti-apoptotic Bcl2, indicating that
this axis confers essential survival signals. Enforced
survival of monocytes, plaque phagocytes and foam
cells restored atherogenesis in Cx3cr1/ mice,
emphasising the homeostatic functions of this axis
in atherosclerosis.10 Conversely, deficiency or anti-
body blockade of DC derived CCL17 in hyper-
lipidaemic mice reduced atheroprogression by
expanding Treg cells, whereas CCL17 expression in
DCs restricted Treg cell maintenance to promote
atherosclerosis, identifying CCL17 as a central
regulator of Treg cell homeostasis.11
LEUCOCYTES INVOLVED IN ATHEROGENESIS
Monocytes/macrophages
While monocytes/macrophages predominate the
inflammatory cell infiltrate in atherosclerosis and
have been discussed in detail elsewhere,12 new
cellular players have recently been uncovered in
recent years, with hitherto underappreciated cell
populations emerging as contributors to disease
development. In addition, the important role of
different subtypes of activated macrophages has
become evident in diet induced obesity and
atherosclerosis, where the activation state of resi-
dent and newly recruited macrophages may shift
from an alternatively activated M2 phenotype
(polarised through IL4/IL13) to a classical pro-
inflammatory M1 phenotype (responding to IFNg)
to exacerbate disease.8
Neutrophils
Polymorphonuclear leucocytes (neutrophils) have
been detected in aortic fatty streak lesions of
primates and correlate with the incidence and
severity of CAD, and have been localised to human
and mouse atherosclerotic lesions. Convincing
evidence for a proatherogenic role of neutrophils
has recently been disclosed in the initial phase of
atherosclerosis in mice.13 It was furthermore
demonstrated that hyperlipidaemia triggers
neutrophilia by stimulating granulopoiesis and
bone marrow egress. Moreover, a disturbed lipid
balance facilitates their recruitment to lesions, as
shown in bone marrow ABC transporter deficient
mice, which showed pronounced neutrophil infil-
tration upon peripheral inflammatory signals.
Neutrophils can subsequently promote monocyte
recruitment. Furthermore, a link between neutro-
phils and coagulation has been provided by
Box 2 Cytokines and chemokines in atherosclerosis: functions in cell
recruitment and beyond
< Inflammatory cytokines, such as macrophage migration inhibitory factor (MIF)
and type I interferons, and co-stimulatory molecules can critically promote
inflammation and atherogenesis.
< Signature combinations of chemokines and their heteromers act in a spatial-
temporal manner to recruit leucocyte subsets via specific chemokine
receptors, eg, CCL5/CXCL4 via CCR5.
< Chemokines in addition control post-recruitment cell homeostasis, eg,
CX3CL1/CX3CR1 drives monocyte survival; the chemokine CCL17 restricts
the maintenance of Tregs.
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evidence that neutrophil serine proteases along
with externalised nucleosomes promote intravas-
cular thrombus growth in vivo by enhancing tissue
factor and factor XII dependent coagulation
through proteolysis of the tissue factor pathway
inhibitor. The continued presence of neutrophils in
advanced plaques may thus contribute to large
vessel thrombosis as a trigger for myocardial
infarction and stroke.2 8
Dendritic cells
DCs are another cell population gaining recent
attention in regard to their role in atherosclerosis.
This cell population constitutes a heterogeneous
group that includes several distinct subsets defined
by surface marker expression profiles. A DC based
network is detectable in the intima of healthy
human arteries and in the aorta of mice, mainly
localised to atherosclerosis prone regions. Resident
intimal CD11c+ DCs accumulate lipids and may be
the first cells to form foam-like cells in the intima
within days of hyperlipidaemia. However, although
DCs are bona fide antigen presenting cells, they
share phenotypic and functional features with
macrophages. A distinction between macrophages
and DCs thus remains controversial and confounded
by their plasticity. Notably, a prolonged DC lifespan
by human Bcl2 expression resulted in increased
conventional DC numbers and reduced plasma
cholesterol concentrations, whereas short term
depletion of DCs in Apoe/ mice increased hyper-
cholesterolaemia. This implicates conventional DCs
in cholesterol homeostasis and atherogenic effects.
Mature DCs further accumulate during athero-
progression and cluster with Tcells in the shoulder
and rupture prone plaque regions. Moreover, aortic
CD11c+ DCs have been shown to trigger antigen
specific T cell proliferation. By sensing atherogenic
danger signals and antigen internalisation, DCs
may be ideally positioned at the crossroads of
innate and adaptive immunity and may be instru-
mental in orchestrating a switch from tolerance to
adaptive immunity activation.14 Recently, distinct
DC subsets with opposing functions have been
discovered. In advanced plaques, CCL17 expression
by mature DCs restricts Treg cell expansion and
sustains atherosclerosis, identifying the control of
Treg cell homeostasis as an effector mechanism of
CCL17+ DCs in atherogenesis.11 In contrast, aortic
CD103+ DCs are associated with the protection of
atherosclerosis and the maintenance of Tregs.15
T cells
Atherosclerotic plaques feature a clonal expansion
of memory effector T cells, indicating antigen
specific reactions, and can also confer lesion
formation upon reconstitutive transfer. The
importance of antigen specific immune responses in
atherogenesis is widely acknowledged. Moreover,
activation of CD8+ T cells against an SMC
expressed artificial antigen exacerbates atheroscle-
rosis in hyperlipidaemic mice. Ldlr/ mice defi-
cient in the major TH1 differentiating transcription
factor T-bet show a reduced lesion size, indicating
that atheroprogression is driven by a TH1-type
response and its signature cytokines IFNg, IL12,
and IL18. Conversely, numerous studies have
established atheroprotective effects mediated by
Treg cell subsets and their products transforming
growth factor b (TGFb) and IL10. In contrast, data
for TH2 and TH17 cells are less conclusive and
partially contradictory.
B cells
Bone marrow B cell deficiency or splenectomy
aggravates atherosclerosis in mice, whereas splenic
B cell transfer mediates protection in splenectom-
ised recipients. Accordingly, deficiency in bone
marrow IL5, a cytokine that expands natural B1
cells, increases atherosclerosis and reduces oxLDL
reactive immunoglobulin M (IgM) values.
Although oxLDL specific IgG titres correlate with
CAD, oxLDL specific IgM titres are associated with
atheroprotection, whichdlike regressiondcan be
conferred by recombinant antibodies to oxLDL in
mice. Notably, depletion of conventional B2 cells
ameliorates atherosclerosis, whereas transfer of B2
but not B1 cells promotes atherosclerosis,
confirming subset specific effects.
MicroRNAs IN ATHEROGENESIS
microRNAs (miRNAs) that post-transcriptionally
regulate gene expression may in addition add
another dimension in the regulation of cell differ-
entiation and functions. In addition, miRNAs have
emerged as important post-transcriptional regula-
tors of lipid metabolism, and represent a new class
of targets for therapeutic intervention. Recently,
microRNA-33a and b (miR-33a/b) were discovered
as key regulators of metabolic programmes
including cholesterol and fatty acid homeostasis.
These intronic microRNAs are embedded in the
sterol response element binding protein genes,
which code for transcription factors that coordinate
cholesterol and fatty acid synthesis. By repressing
a variety of genes involved in cholesterol export and
fatty acid oxidation, miR-33a/b boost cellular sterol
concentrations.16 Indeed, inhibition of miR-33 by
antagomirs in mice or non-human primates can
promote reverse cholesterol transport to raise HDL
concentrations and possibly mediate regression of
atherosclerosis.
The analysis of miRNA expression patterns in
arterial lesions and atherosclerotic plaques has
revealed fundamental changes in the miR signature
comprising many different miRs. Moreover, single
miRNAs have been pinpointed to exert a significant
impact on neointimal lesion formation, for
example, miR-143 and miR-145, and studies
addressing the function of miRNAs in the devel-
opment of atherosclerosis are ongoing.17 Recent
miRNA profiling studies further revealed that
circulating concentrations of vascular derived
microRNAs, including miR-126, were reduced in
individuals with CAD.2 Interestingly, miR-126 or
miR-126 carrying endothelial apoptotic bodies have
been identified as being atheroprotective in mice,
promoting CXCR4 dependent mobilisation and
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lesional incorporation of angiogenic progenitor
cells. By repressing RGS16, miR-126 unleashes
autoregulatory CXCR4 signalling and increases
endothelial production of CXCL12, a mediator of
stem cell mobilisation and homing.18 The recruit-
ment of such circulating (or locally residing) cyto-
kine releasing progenitor cells may support
endothelial regeneration or modulate inflammation,
but may contribute to neovascularisation in
advanced plaque stages.8 These findings support
the development of microRNA antagonists as
potential therapeutic agents for the treatment
of dyslipidaemia, atherosclerosis, and related
metabolic disease.
MICROBIOTIC FLORA IN THE GUT
The intestinal microbiotic flora performs essential
functions in nutrient processing and assists host
immune responses, but it has also been linked to
metabolic and immune disorders, prompting
studies of its relation to human disease. A recent
metabolomics approach identified the dietary lipid
phosphatidylcholine and its metabolites choline,
betaine, and trimethylamine N-oxide (TMAO) as
risk factors for cardiovascular disease. In mice,
a choline-rich diet increased TMAO values and
atherosclerosis, depending on gut flora activity, as
shown by broad spectrum antibiotic treatment.
Although earlier antibiotic trials failed to reduce
event rates in humans with CAD, specific targeting
of bacterial species responsible for choline metab-
olism using selective antibiotics or probiotics might
have therapeutic value for cardiovascular disease.19
Detailed analysis of the relations between gut
microbiota, host metabolism, and atherosclerosis
may allow for subtle microbiota manipulation as




The high incidence of atherosclerosis related
cardiovascular disease and CAD imposes an enor-
mous burden on healthcare systems. The estab-
lished therapeutics against atherosclerosis are
largely focused on alleviating hypertension and
hyperlipidaemia or controlling haemostasis to
prevent thrombotic complications (table 1).2 20
Treatment with statins for secondary prevention
in patients with CAD can result in a pronounced
risk reduction, which correlates with lowering of
LDL cholesterol. Statins exert a pleiotropy of anti-
inflammatory actions, improve endothelial func-
tion and reduce plaque lipids and thrombogenicity,
thereby limiting atheroprogression and increasing
plaque stability. Aggressive lipid lowering by high
dose atorvastatin decreases high sensitivity C
reactive protein (hs-CRP) serum concentrations and
causes regression of atheromas. This clinical benefit
is extended to primary prevention in patients with
LDL cholesterol concentrations <130 mg/dl (<3.4
mmol/l) but elevated hs-CRP, where rosuvastatin
significantly reduces major cardiovascular event
rates, with reductions in both LDL cholesterol and
hsCRP indicating successful treatment. In acute
coronary syndrome (ACS), aggressive statin treat-
ment also lowered the incidence of primary end
points including myocardial infarction, with the
most substantial benefit in patients with declines
in both LDL cholesterol and CRP. In statin treated
patients with low HDL cholesterol, extended
release of nicotinic acid (niacin) may shift the lipid
Table 1 Atherosclerosis therapy
Compound or method Mechanism Status or effect
Established therapies
Statins, eg, atorvastatin, rosuvastatin Inhibit cholesterol synthesis; anti-inflammatory Primary and secondary prevention
Nicotinic acid (niacin) Inhibits fat breakdown and increases
high density lipoprotein (HDL) cholesterol;
anti-inflammatory
Secondary prevention
Aspirin, clopidogrel, prasugrel, ticagrelor Inhibit platelet aggregation Secondary prevention
b-blockers, renin―angiotensin system inhibitors Antihypertensive Secondary prevention
Emerging therapeutic approaches
HDL mimetics, eg, apoa1-Milano Promote cholesterol efflux; anti-inflammatory Clinical phase 1/2
Darapladib (Lp-PLA2 inhibitor) Decreases atherogenic lipid production Clinical phase 3
Anakinra IL1 receptor antagonist Clinical phase 2
Canakinumab Blocking IL1b antibody Clinical phase 3 (CANTOS)
Methotrexate Immunosuppressive Clinical phase 3 (CIRT)
Thiazolidinediones (PPAR (peroxisome
proliferator activated receptor) agonists)
Anti-inflammatory Increased risk of heart failure
and myocardial infarction
CETP (cholesteryl ester transfer protein)
inhibitors, eg, anacetrapib
Inhibit cholesterol transport from HDL to
low density lipoprotein (LDL)
Torcetrapib raised blood pressure
Clinical phase 3
Novel experimental strategies
Maraviroc CCR5 antagonist Approved for HIV treatment
MLN1202 Blocking CCR2 antibody Clinical phase 2
CT-2009 Inhibits CCL5-CXCL4 and atherosclerosis in mice
Blocking macrophage migration inhibitory
factor (MIF) receptor binding
Induces lesion stabilisation and regression in mice
Blocking the CD40-TRAF6 interaction Limits unstable atherosclerosis in mice
Immunisation CCL17 inhibition Protective antibodies and Treg expansion,
inhibits atherosclerosis in mice
Preclinical and early clinical phase
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balance in favour of HDL cholesterol to promote
regression of the carotid intima―media thickness,
but may also exert anti-inflammatory effects
through the niacin receptor GPR109A in immune
cells.
Platelet inhibition with aspirin has proved an
enduring pillar for secondary prevention in patients
with ACS, a benefit enhanced by other antiplatelet
agents such as clopidogrel, prasugrel or ticagrelor.
However, its suitability for primary prevention of
atheroprogression may be limited owing to the
atherogenic effects of the platelet secretome, which
remain unaltered, as these drugs primarily interfere
with aggregation. Furthermore, trials suggest that
antihypertensive ß-blockers can lower mortality
from myocardial infarction and delay atheroprog-
ression. Likewise, interference with the renin―
angiotensin system improves endothelial function
and reduces coronary event rates disproportionately
to lower blood pressure, supporting direct
atheroprotective effects.2 20
A significant number of novel therapeutic strat-
egies for the treatment of atherosclerosis continue
to emerge, namely HDL mimetics, CETP (choles-
teryl ester transfer protein) inhibitors, Lp-PLA2
inhibitors, IL1 receptor antagonists, immunosup-
pressives or PPAR (peroxisome proliferator acti-
vated receptor) agonists, but also experimental
approaches such as cytokine and chemokine
(receptor) antagonists or immunisation (table 1).
Given the enormous cost of clinical end point
studies beyond lipid lowering, the development of
such anti-atherosclerotic drug candidates mandates
a stringent evaluation of their effectiveness and
largely relies on surrogate markers. Although
a variety of soluble, imaging or functional
biomarkers is available, their predictability in phase
2 for atherosclerosis outcomes in phase 3 studies
remains limited. Hence, new biomarkers should be
developed to complement existing ones or to
combine multiple biomarkers in an integrated
approach to monitor such new therapies.
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